Related Experiment Video

Updated: Jun 5, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor

Sandra Cantilena1,2, Mohamed AlAmeri2,3, Noelia Che2

  • 1Hemispherian AS, 0585 Oslo, Norway.

Cancers
|December 17, 2024
PubMed

Insights

Menin inhibitors show promise for KMT2A-rearranged leukemias, but resistance is a challenge. Combination therapies targeting DOT1L, BRD4, MYC, and other pathways offer new hope for overcoming resistance and improving patient survival.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • KMT2A-rearranged leukemias are aggressive acute leukemias with poor prognosis.
  • Menin inhibitors target the KMT2A-menin interaction crucial for leukemogenesis.
  • Therapeutic resistance, driven by menin mutations or alternative pathways, limits current treatment efficacy.

Purpose of the Study:

  • To review combination therapies for overcoming resistance in KMT2A-rearranged leukemias.
  • To explore novel therapeutic strategies targeting key oncogenic pathways.
  • To propose a comprehensive approach for improved patient outcomes.

Main Methods:

  • Review of current literature on KMT2A-rearranged leukemias and therapeutic resistance.
  • Analysis of potential combination targets including DOT1L, BRD4, MYC, KMT2A-fusion proteins, and c-MYB.
  • Exploration of targeting the transcriptional and epigenetic network.

Main Results:

  • Combination therapies offer potential to overcome resistance to menin inhibitors.
  • Targeting DOT1L, BRD4, MYC, KMT2A-fusion proteins, and c-MYB are promising strategies.
  • A multi-targeted approach can disrupt oncogenic pathways and enhance treatment efficacy.

Conclusions:

  • Combination therapies are essential for improving outcomes in KMT2A-rearranged leukemias.
  • Targeting multiple points in the leukemic network can reduce resistance and improve survival.
  • A comprehensive therapeutic paradigm is needed for durable remissions and better patient prognosis.
Keywords:
KMT2A-rearranged leukemiaacute myeloid leukemiacombination therapiesmenin inhibitorstargeted therapiestherapeutic resistance

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.2K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K